← All stocks

Xeris Biopharma Holdings, Inc.

XERS Net selling
CIK 0001867096 #2214 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$4.76M
$3.31M on a plan · $349.66K straight out of an exercise
Sold at will
$1.10M
2 of 29 sales
Net
−$4.76M
−$1.10M against sales at will

By person

14 insiders · 34 transactions
33.1×

John Shannon holds 33.1 times base salary in stock. $24.64M of shares against $742.33K in salary for 2025.

Salary from the company's own proxy. The shares are what John Shannon last reported holding, valued at $8.50, the price Common Stock was last bought or sold at on the open market here, on 1 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Hecht Beth
See Remarks
$1.31M (12) scheduled
−$1.31M
1,127,796
0.6186%
$9.59M
−18.9%
McCulloch Kevin
See Remarks
$1.09M (4) scheduled
−$1.09M
1,664,208
0.9128%
$14.15M
+1.4%
JOHNSON JOHN
Director
$1.07M (2)
−$1.07M
707,276
0.3879%
$6.01M
−20.6%
Pieper Steven
See Remarks
$468.18K (4) scheduled
−$468.18K
1,356,053
0.7438%
$11.53M
−4.8%
Shannon John Patrick Jr
See Remarks
$349.66K (2) scheduled
−$349.66K
2,898,933
1.59%
$24.64M
+34.5%
BORMANN-KENNEDY BARBARA-JEAN ANNE
Director
$203.92K (2) scheduled
−$203.92K
150,693
0.0827%
$1.28M
+40.2%
HALKUFF DAWN
Director
$121.89K (1) scheduled
−$121.89K
119,193
0.0654%
$1.01M
+10.9%
PERSKY MARLA
Director
$91.43K (1) scheduled
−$91.43K
150,693
0.0827%
$1.28M
+40.2%
Brady James Aloysius
Director
$60.04K (1) scheduled
−$60.04K
113,359
0.0622%
$963.55K
Nguyen Anh Tu
See Remarks
395,023
0.2167%
$3.36M
+30.4%
JOHNSON KENNETH ERLAND
See Remarks
320,446
0.1758%
$2.72M
−14.4%
Kong Garheng
Director
238,337
0.1307%
$2.03M
+45.2%
SHERMAN JEFFREY W
Director
219,188
0.1202%
$1.86M
+33.3%
KREHER NERISSA
Director
33,582
0.0184%
$285.45K
Insider
Date
Role
Action
Shares
Price
Amount
Hecht Beth
2 Feb 2026
See Remarks
Sell
16,667
$7.45
$124.15K
JOHNSON JOHN
19 Dec 2025
Director
Sell
135,400
$7.22
$977.02K

What was left out

Form 4 filings counted 40
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 25
Sales straight out of an exercise 2
Sales at will 2
Transactions with no price 0
Shares from compensation/vesting 2,432,659
History held since 5 Oct 2021